Kura Oncology (KURA) versus Its Rivals Critical Survey
Kura Oncology (NASDAQ: KURA) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Kura Oncology to related companies based on the strength of its profitability, earnings, analyst recommendations, valuation, dividends, risk and institutional ownership.
Earnings & Valuation
This table compares Kura Oncology and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Kura Oncology||N/A||-$27.56 million||-10.00|
|Kura Oncology Competitors||$290.27 million||$35.99 million||61.13|
Institutional and Insider Ownership
64.3% of Kura Oncology shares are owned by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 21.8% of Kura Oncology shares are owned by insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Kura Oncology has a beta of 4.89, meaning that its share price is 389% more volatile than the S&P 500. Comparatively, Kura Oncology’s rivals have a beta of 2.80, meaning that their average share price is 180% more volatile than the S&P 500.
This table compares Kura Oncology and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Kura Oncology Competitors||-5,189.81%||-162.78%||-35.24%|
This is a summary of recent ratings for Kura Oncology and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Kura Oncology Competitors||917||3335||11836||237||2.70|
Kura Oncology presently has a consensus target price of $18.30, suggesting a potential upside of 18.06%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.29%. Given Kura Oncology’s rivals higher probable upside, analysts clearly believe Kura Oncology has less favorable growth aspects than its rivals.
Kura Oncology beats its rivals on 7 of the 13 factors compared.
About Kura Oncology
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.